PCI 3.06.26
Wallonia

Current Features

Upcoming Events

Auto Draft
Auto Draft
Elrig
Auto Draft
CPHI
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem

Current Features

Advertisement

Current Features

Upcoming Events

Auto Draft
Auto Draft
Elrig
Auto Draft
CPHI
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem
Current Features

The Critical Role of Fill-Finish in Large-Molecule Manufacturing

The biologics sector has moved from a specialist segment to one of the most dynamic areas in pharmaceutical manufacturing. Recent market estimates place the biol...
Continue Reading →
Current Features

Streamlining Biologics Technology Transfer Through Integrated Operational Models

To consistently reproduce high-quality biologics across operations, technology transfer in new environments requires disciplined coordination across development,...
Continue Reading →
Current Features

From Depression to Deep-Learning – Leveraging iPSC and AI platforms for Evidence-Based Depression Treatment

Psychiatry has spent a century trying to treat what it could not see. Patient-derived neurons are about to change that. Depression touches a staggering portio...
Continue Reading →
Current Features

Blood-Based mRNA Testing for the Diagnosis of Schizophrenia and Bipolar Disorder

Mental health diagnostics have been in crisis for some time now due to increasing patient loads, lack of definitive diagnostics and adverse societal impact. This...
Continue Reading →
Current Features

Counting Stars: Why an Astrocentric Perspective Matters for CNS Drug Discovery

Standard of care treatments for neurological disorders like Parkinson’s still rely on therapeutic principles established over 50 years ago,12 and these treatment...
Continue Reading →
Current Features

Essential DMPK Approaches for IND Success

Ninety per cent of drug candidates that enter clinical trials never reach patients. Developing a single new medicine now costs more than a billion dollars. Too o...
Continue Reading →
Current Features

From Signal to Standard: The Rising Structural Role of Biomarkers in Oncology Trials

From Afterthought to Design Driver Over the past decade, biomarkers have moved from the margins of oncology clinical trials into their structural core. Where ...
Continue Reading →
Current Features

Turning Oncology Data into Better Development Decisions

Oncology remains one of the highest-attrition areas in drug development, with only a small minority of candidates entering clinical testing going on to reach app...
Continue Reading →
Current Features

When the Gene Editing Guide is the Drug

The rapid evolution of gene therapies and gene editing modalities in particular is challenging how personalised medicines are developed and evaluated. Many rare ...
Continue Reading →

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Company Profiles